Homepage

CHAPTER 1
CHAPTER 2
CHAPTER 3
CHAPTER 4
CHAPTER 5
CHAPTER 6
CHAPTER 7
CHAPTER 8
CHAPTER 9
CHAPTER 10
CHAPTER 11
CHAPTER 12
CHAPTER 13
CHAPTER 14
CHAPTER 15
CHAPTER 16
CHAPTER 17
CHAPTER 18
CHAPTER 19
CHAPTER 20
CHAPTER 21

Systemic antifungal drugs

John R. Graybill

Infectious Diseases Division, University of Texas Health Science Center, San Antonio, Texas, USA
In recent years there have been major new developments in systemic antifungal drugs. For amphotericin B there are several lipid formulations recently developed. These clearly reduce infusion and nephrotoxicity, allowing large doses to be administered safely. It remains less clear how much more effective are the lipid formulations as compared to amphotericin B desoxycholate. For the triazoles, itraconazole has been reformulated into a solution which improves oral absorption and can also be given intravenously. The clinical impact of this is still uncertain. Voriconazole and posaconazole are two new broad spectrum triazoles which will compete with itraconazole for activity in fluconazole resistant yeast and mycelial pathogens. Finally, a new class, the echinocandins, is under Phase III study.
Three competitors are highly active against Candida and some mycelial pathogens. Their ultimate role has not been defined. All of these developments provide the clinician with an increasing array of choices to use in the expanding word of systemic mycoses.
 
 

PDF file

In: Kushwaha RKS, Guarro J (Eds.). Biology of Dermatophytes and other Keratinophilic Fungi.
Revista Iberoamericana de Micología, Bilbao, 2000.
 
 

2000-2014@ Revista Iberoamericana de Micología. All rights reserved.